Rocket Doctor AI Net Debt per Share
Delisted
The Net Debt per Share of Rocket Doctor AI (TRUE.CN) as of Nov 16, 2026 is -0.01 CAD.
Get this data via API
Financial Data API
Net Debt per Share
-0.01CAD
YoY
726.32%
Last updated:
Net Debt per Share of Rocket Doctor AI is 2024 -0.01 CAD. Net Debt per Share of Rocket Doctor AI was 2023 -0.00 CAD. It decreases by 726.32% lower compared to the previous year.
The Rocket Doctor AI Net Debt per Share history
3 Years
10 Years
25 Years
Max
Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
-0.00 CAD
Jan 1, 2018
-0.00 CAD
Jan 1, 2019
-0.01 CAD
Jan 1, 2020
-0.00 CAD
Jan 1, 2021
-0.01 CAD
Jan 1, 2022
0.01 CAD
Jan 1, 2023
-0.00 CAD
Jan 1, 2024
-0.01 CAD
| YEAR | Net Debt per Share | YoY |
|---|---|---|
| -0.01CAD | +726.32% | |
| -0.00CAD | -123.18% | |
| 0.01CAD | -161.50% | |
| -0.01CAD | +193.28% | |
| -0.00CAD | -39.35% | |
| -0.01CAD | +1,945.24% | |
| -0.00CAD | +129.09% | |
| -0.00CAD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Rocket Doctor AI Stock analysis
What does Rocket Doctor AI do? Treatment.com AI Inc generates revenue through its Treatment Digital Health App, a symptom assessment tool developed by a global team of doctors and engineers. The app provides predictive health insights using disease rate estimates, geographic variation data, and medical research, targeting patients and caregivers seeking informed health decisions. The company also offers medical education solutions and clinical advisor services, serving healthcare professionals and institutions globally. Revenue streams include subscriptions for app access and tailored medical education programs.
The Treatment Digital Health App is designed for widespread use, offering advanced medical knowledge access to users worldwide. Medical clinic solutions are integrated into the platform, supporting healthcare providers in decision-making. Clinical advisor services leverage the AI platform to assist clinics and institutions with specialized medical guidance. These offerings are marketed to healthcare consumers, clinics, and educational institutions as part of the company's global healthcare technology strategy.
Treatment.com AI Inc's business model focuses on AI-driven health solutions, with the Treatment Digital Health App as its primary product. The app's predictive health assessments are updated regularly by medical professionals, ensuring relevance and accuracy. The company monetizes through direct consumer subscriptions and B2B partnerships with medical clinics and educational providers, emphasizing global accessibility and evidence-based medical insights. Rocket Doctor AI is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Rocket Doctor AI stock
Net Debt per Share of Rocket Doctor AI is -0.01 CAD in 2024.
On Eulerpool you can find the complete historical development of Net Debt per Share Rocket Doctor AI since 2006 – with annual values, charts, and detailed analysis.
Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Other — Rocket Doctor AI
All Key Metrics — Rocket Doctor AI
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth